These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1477 related items for PubMed ID: 15149345

  • 1. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [Abstract] [Full Text] [Related]

  • 2. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM, RENAAL Study Group.
    Arch Intern Med; 2003 Jul 14; 163(13):1555-65. PubMed ID: 12860578
    [Abstract] [Full Text] [Related]

  • 3. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
    Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D.
    J Am Soc Nephrol; 2007 May 14; 18(5):1540-6. PubMed ID: 17409317
    [Abstract] [Full Text] [Related]

  • 4. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.
    Circulation; 2004 Aug 24; 110(8):921-7. PubMed ID: 15302780
    [Abstract] [Full Text] [Related]

  • 5. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.
    de Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP, Chan J, Remuzzi G, Brenner BM, Shahinfar S.
    Kidney Int; 2006 May 24; 69(9):1675-82. PubMed ID: 16572114
    [Abstract] [Full Text] [Related]

  • 6. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
    Keane WF, Lyle PA, Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.
    Am J Kidney Dis; 2003 Mar 24; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
    [Abstract] [Full Text] [Related]

  • 7. Losartan in diabetic nephropathy.
    Perico N, Ruggenenti P, Remuzzi G.
    Expert Rev Cardiovasc Ther; 2004 Jul 24; 2(4):473-83. PubMed ID: 15225108
    [Abstract] [Full Text] [Related]

  • 8. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
    Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ.
    Hypertension; 2011 Jul 24; 58(1):2-7. PubMed ID: 21632472
    [Abstract] [Full Text] [Related]

  • 9. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
    Ruilope LM, Segura J.
    Clin Ther; 2003 Dec 24; 25(12):3044-64. PubMed ID: 14749145
    [Abstract] [Full Text] [Related]

  • 10. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
    Kurokawa K, Chan JC, Cooper ME, Keane WF, Shahinfar S, Zhang Z.
    Clin Exp Nephrol; 2006 Sep 24; 10(3):193-200. PubMed ID: 17009077
    [Abstract] [Full Text] [Related]

  • 11. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.
    Chan JC, Wat NM, So WY, Lam KS, Chua CT, Wong KS, Morad Z, Dickson TZ, Hille D, Zhang Z, Cooper ME, Shahinfar S, Brenner BM, Kurokawa K, Asian RENAAL Study Investigators.
    Diabetes Care; 2004 Apr 24; 27(4):874-9. PubMed ID: 15047641
    [Abstract] [Full Text] [Related]

  • 12. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B.
    Curr Med Res Opin; 2004 Mar 24; 20(3):333-40. PubMed ID: 15025842
    [Abstract] [Full Text] [Related]

  • 13. Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.
    Shahinfar S, Dickson TZ, Ahmed T, Zhang Z, Ramjit D, Smith RD, Brenner BM, RENAAL Investigators.
    Kidney Int Suppl; 2002 Dec 24; (82):S64-7. PubMed ID: 12410858
    [Abstract] [Full Text] [Related]

  • 14. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Zanella MT, Ribeiro AB.
    Clin Ther; 2002 Jul 24; 24(7):1019-34. PubMed ID: 12182249
    [Abstract] [Full Text] [Related]

  • 15. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators.
    N Engl J Med; 2001 Sep 20; 345(12):861-9. PubMed ID: 11565518
    [Abstract] [Full Text] [Related]

  • 16. High level of proteinuria during treatment with renin-angiotensin inhibitors is a strong predictor of renal outcome in nondiabetic kidney disease.
    Xie D, Hou FF, Fu BL, Zhang X, Liang M.
    J Clin Pharmacol; 2011 Jul 20; 51(7):1025-34. PubMed ID: 20978279
    [Abstract] [Full Text] [Related]

  • 17. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S.
    Ugeskr Laeger; 2001 Oct 01; 163(40):5514-9. PubMed ID: 11601117
    [Abstract] [Full Text] [Related]

  • 18. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
    Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D.
    Am J Kidney Dis; 2014 Feb 01; 63(2):244-50. PubMed ID: 24210590
    [Abstract] [Full Text] [Related]

  • 19. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.
    Mohanram A, Zhang Z, Shahinfar S, Lyle PA, Toto RD.
    Kidney Int; 2008 Mar 01; 73(5):630-6. PubMed ID: 18094675
    [Abstract] [Full Text] [Related]

  • 20. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
    Schutte E, Lambers Heerspink HJ, Lutgers HL, Bakker SJ, Vart P, Wolffenbuttel BH, Umanath K, Lewis JB, de Zeeuw D, Gansevoort RT.
    Am J Kidney Dis; 2015 Sep 01; 66(3):450-8. PubMed ID: 25987260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.